Drug Development

Clinical Trials Market Trends Market Competition Alzheimer's Treatment Weight Loss Drugs FDA Approval Oncology Biosimilars Regulatory Approval Pharmaceutical Research Weight-loss Drugs Personalized Medicine Larger-Molecule Drugs AI in Drug Discovery Phase 3 Clinical Trials Pediatric Medication Clinical Studies Research and Development Cellular Biology HIV Prevention Respiratory Diseases Cancer Therapies Innovative Therapies Regulatory Review Vaccine Development Antiviral Drugs Cancer Treatments Acquisition Strategies Weight Management Gene Therapy Preventive Medicine Biopharmaceuticals Pipeline Expansion Oral Medications Drug Screening Combination Therapies FDA Approvals Non-invasive Techniques Antidepressants Cost Analysis New Products Clinical Therapies Obesity Drugs

Bristol Myers and J&J Halt Milvexian Heart-Attack Trial After Futility Finding

Two remaining Phase 3 studies in atrial fibrillation and secondary stroke prevention continue, with topline results expected in 2026.

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws